Stockscreener 앱 받기
7.28
8.17%
0.55
전일 마감가:
$6.73
열려 있는:
$6.75
하루 거래량:
1.35M
Relative Volume:
3.77
시가총액:
$479.80M
수익:
-
순이익/손실:
$-44.47M
주가수익비율:
-7.1506
EPS:
-1.0181
순현금흐름:
$-33.50M
1주 성능:
+6.74%
1개월 성능:
+25.30%
6개월 성능:
-10.01%
1년 성능:
+37.91%
1일 변동 폭
$6.64
$7.38
1주일 범위
$6.64
$7.38
52주 변동 폭
$5.04
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.28 | 445.53M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 개시 | William Blair | Outperform |
| 2025-07-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 개시 | H.C. Wainwright | Buy |
| 2025-06-16 | 개시 | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
모두보기
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Eupraxia Pharmaceuticals Stock Falls 4.12% as Investors Weigh Clinical Progress Against Biotech Development and Financing Risk - kalkine.ca
Eupraxia Slides as Biotech Traders Take Risk Off the Table — What Could Trigger the Next Move? - kalkine.ca
Eupraxia Pharmaceuticals Faces Fresh Downside Pressure as Clinical Execution Risk Clouds the EoE Story - kalkine.ca
Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - kalkine.ca
Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review - vinanet.vn
Eupraxia Pharmaceuticals Market Sentiment - Benzinga France
What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday? - Wealth Awesome
Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Edges Higher to $6.72 as Biotech Sector Holds SteadyEqual Weight ETF - Vinanet
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis - TipRanks
Eupraxia Pharmaceuticals (EPRX) Holds Gains as Shares Trade Near $6.72MFI Overbought - vinanet.vn
Eupraxia Pharmaceuticals (EPRX) Advances 0.75% as Price Approaches Key ResistancePost-Earnings Moves - vinanet.vn
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Eupraxia Pharmaceuticals Inc EPRX Earnings Beat Estimates by 0.0% - Wealth Awesome
Eupraxia reports symptom improvements in EoE trial analysis - Investing.com
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients - Investing News Network
Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients - thecanadianpressnews.ca
Eupraxia reports symptom improvements in EoE trial analysis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals (EPRX) shows durable EoE symptom relief in RESOLVE trial - Stock Titan
Eupraxia Pharmaceuticals Inc (TSX:EPRX) Shares Decline as Clinical Development Risks and Biotechnology Market Volatility Pressure Sentiment - kalkine.ca
Eupraxia's RESOLVE Cohorts 7-9: No Severe Swallowing Pain at Weeks 24 or 52 - Stock Titan
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eupraxia Q2 EPS beats estimate despite wider net loss - scanx.trade
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results - MarketBeat
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects - TipRanks
Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M - Stock Titan
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results - GlobeNewswire
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - finance.yahoo.com
Will Eupraxia Pharmaceuticals Inc (EPRX) Beat Earnings Estimates in Its Next Report? - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eupraxia Pharmaceuticals (NASDAQ: EPRX) sets up US$300M mixed securities shelf - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Edges Lower to $6.48, Holding Between Support and ResistancePut Wall - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) to Post Earnings on Tuesday - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Consolidates Near $6.50 as Investors Await Clinical MilestonesUnusual Put Volume - Vinanet
Bloom Burton Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Edges Higher: Modest Gain Amid Biotech Sector WatchFactor Rotation - dars.gov.et
276,000 Shares in Eupraxia Pharmaceuticals Inc. $EPRX Acquired by DV Trading LLC - MarketBeat
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
Ally Bridge Group NY LLC Raises Stock Holdings in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
Eupraxia Pharmaceuticals Inc (EPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rubric Capital Management LP Takes $5 Million Position in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
Eupraxia Pharmaceuticals Inc (EPRX) Institutional Confidence - TradingKey
Why Eupraxia Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.810|Chg%:-0.490 - TradingKey
Eupraxia Pharmaceuticals, Inc. Revenue Breakdown – TSX:EPRX - TradingView
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):